Temsirolimus: A safety and efficacy review

Expert Opinion on Drug Safety

Volumn 11, Issue 5, 2012, Pages 861-879

  Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

carcinoma; cell; renal; temsirolimus

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CARBAMAZEPINE; DEXAMETHASONE; EVEROLIMUS; KETOCONAZOLE; PHENOBARBITAL; PHENYTOIN; RAPAMYCIN; RIFAMPICIN; TEMSIROLIMUS;

ABDOMINAL PAIN; ABSCESS; ANAPHYLAXIS; ANEMIA; ANGIOGENESIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APNEA; APOPTOSIS; ARTERIAL THROMBOEMBOLISM; ASTHENIA; BLEEDING; BRAIN HEMORRHAGE; BRONCHITIS; BULLOUS SKIN DISEASE; CANCER PROGNOSIS; CANCER SURVIVAL; CELLULITIS; COUGHING; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; ECZEMA; EDEMA; ERYTHEMA; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; FATIGUE; FEVER; FLUSHING; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLOMERULOSCLEROSIS; GLOSSITIS; HEPATITIS B; HERPES SIMPLEX; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; HYPOTENSION; KIDNEY CARCINOMA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; MACULOPAPULAR RASH; MONOTHERAPY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; NAIL DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PARONYCHIA; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMARKETING SURVEILLANCE; PROGRESSION FREE SURVIVAL; PROTEINURIA; PRURITUS; PUSTULE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THORAX PAIN; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM; VIRUS INFECTION; VOMITING; WOUND HEALING IMPAIRMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG EVALUATION; DRUG MONITORING; HUMANS; KIDNEY NEOPLASMS; PRODUCT SURVEILLANCE, POSTMARKETING; PROGNOSIS; PROTEIN KINASE INHIBITORS; SIROLIMUS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TUMOR BURDEN;

EID: 84865494478     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.713344     Document Type: Review

References (106)

1. Molina AM, Motzer RJ. Clinical practice guidelines for the treatment of metastatic renal cell carcinoma: today and Tomorrow. Oncologist 2011;16(Suppl 2):45-50
2. Hutson TE. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence. Oncologist 2011;16(Suppl 2):14-221
3. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81 (Pubitemid 46849157)
4. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372(9637):449-56
5. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006;12:7215-20 (Pubitemid 46095391)
6. Brugarolas J. Renal-cell carcinoma-molecular pathways and therapies. N Engl J Med 2007;356:185-7
7. Pantuck AJ, Seligson DB, Klatte T, et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 2007;109:2257-67 (Pubitemid 46801555)
8. Dancey JE. Therapeutic targets MTOR and related pathways. Cancer Biol Ther 2006;5(9):1065-73 (Pubitemid 44773684)
9. Toschi A, Lee E, Gadir N, et al. Differential dependence of hypoxia-inducible factors 1{alpha} and 2 {alpha} on mTORC1 and mTORC2. J Biol Chem 2008;283(50):34495-9
10. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006;5(8):671-88 (Pubitemid 44151605)
11. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101 (Pubitemid 40262113)
12. Yatscoff RW, LeGatt DF, Kneteman NM. Therapeutic monitoring of rapamycin: a new immunosuppressive drug. Ther Drug Monit 1993;15(6):478-82 (Pubitemid 23347236)
13. Seghal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S
14. Del Bufalo D, Ciuffreda L, Trisciuoglio D, et al. Antiangiogenic potential of the mammalian Target of Rapamycin Inhibitor Temsirolimus. Cancer Res 2006;66:5549-54 (Pubitemid 43927103)
15. Molecular structure temsirolimus. Available from: http://en.wikepedia. org/wiki/File:Temsirolimus.png [Last accessed 12 May 2012]
16. Le Tourneau C, Faivre S, Serova M, Raymond E. MTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Can 2008;99:1197-203
17. Dudkin L, Dilling MB, Cheshire PJ, et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001;7:1758-64 (Pubitemid 32708646)
18. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000;103(2):253-62
19. Thomas G, Hall MN. TOR signalling and control of cell growth. Curr Opin Cell Biol 1997;9(6):782-7 (Pubitemid 27517266)
20. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48 (Pubitemid 38579480)
21. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124(3):471-84 (Pubitemid 43199434)
22. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12(1):122-7 (Pubitemid 43050086)
23. Hidalgo M, Rowinsky EK. The rapamycin sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000;19:6680-6 (Pubitemid 32197708)
24. Klumpen HJ, Beijnen JH, Gurney H, Schellens JHM. Inhibitors of mTOR. Oncologist 2010;15:1262-9
25. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22:2336-47 (Pubitemid 41115390)
26. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase ii study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22:909-18 (Pubitemid 41103603)
27. TORISEL® Prescribing Information, Pfizer, June 2011
28. Cai P, Tsao R, Ruppen ME. In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 2007;35:1554-63 (Pubitemid 47296048)
29. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. Toxicology 1995;104:1-8 (Pubitemid 26016371)
30. Boni JP, Leister C, Burns J, Hug B. Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus. Br J Cancer 2008;98:1797-802 (Pubitemid 351748841)
31. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003;9(8):2887-92 (Pubitemid 36993245)
32. Cho D, Signoretti S, Dabora S, et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007;5(6):379-85 (Pubitemid 47584475)
33. Figlin RA, de Souza P, McDermott D, et al. Analysis of PTEN and. HIF-1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-a. Cancer 2009;115:3651-60
34. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase (LDH) as a biomarker for survival with mTOR inhibition in patients with metastatic renal cell carcinoma. J Clin Oncol 2010;28(15s Suppl):abstract 4631
35. Galanis E, Buckner JC, Maurer M, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005;23:5294-304 (Pubitemid 46206983)
36. Lee CK, Marschner I, Simes J, et al. Increase in cholesterol predicts survival advantage in renal cellcarcinoma patients treated with temsirolimus. Clin Can Res 2012;18:3188-96
37. Cho DC, Atkins MB. Serum cholesterol and mTOR inhibitors: surrogate biomarker or epiphenomenon? Clin Can Res 2012;18:2999-3001
38. Sharpe LJ, Brown AJ. Rapamycin down-regulates LDL-receptor expression independently of SREBP-2. Biochem Biophys Res Commun 2008;373:670-4
39. Hidalgo M, Buckner JC, Erlichman C, et al. A phase i and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 2006;12(19):5755-63 (Pubitemid 44629606)
40. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289-96 (Pubitemid 34032623)
41. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial f temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007;25:3958-64 (Pubitemid 47477274)
42. Kwitkowski VE, Prowell TM, Ibrahim A, et al. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma. Oncologist 2010;15:428-35
43. Medical Research Council Renal Cancer Collaborators. IFN-alpha and survival in metastatic renal carcinoma: early study results of a randomized controlled trial. Lancet 1999;353:14-17
44. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the memorial sloan-kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832-41 (Pubitemid 46224183)
45. Torisel Approval History. Available from: www.drugs.com/history/torisel/ html [Last accessed 4 May 2012]
46. EMA Torisel Approval: Scientific Discussion. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific-Discussion/human/ 000779/WC500039915.pdf [Last accessed 4 May 2012]
47. Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon - a on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009;26:202-9
48. Dutcher JP, Szczylik C, Tannir N, et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN) [abstract]. J Clin Oncol 2007;25(18S):5033
49. Laplante M, Sabatini DM. An emerging role of mTOR in lipid biosynthesis. Curr Biol 2009;19(22):1046-52
50. Wang BT, Ducker GS, Barczak AJ, et al. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc Natl Acad Sci 2011;108:15201-6
51. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008;19:1387-92
52. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 2001;72(5):787-90 (Pubitemid 32879846)
53. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42:1875-80 (Pubitemid 44149096)
54. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011;29:1750-6
55. Eisen T, Sternberg C, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst 2012;104:93-113
56. Hadoux J, Vignot S, De La Mott Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010;4:143-54
57. Launay-Vacher V, Oudard S, Janus N, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management. The Renal Insufficiency and Anticancer Medications (IRMA) Study. Cancer 2007;110:1376-84 (Pubitemid 47435612)
58. Gupta S, Parsa V, Heilbrun L, et al. Safety and efficacy of molecularly targeted agents in patients with metastatic kidney cancer with renal dysfunction. Anticancer Drugs 2011;22:794-800
59. Izzedine H, Boostandoot E, Spano JP, et al. Temsirolimus-induced glomerulopathy. Oncology 2009;76:170-2
60. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: necker hospital 8-year experience. Transpl Proc 2003;35(Suppl 3A):52S-7S (Pubitemid 36547915)
61. Heras M, Fernández-Reyes MJ, Rodríguez A, et al. Acute renal failure in a patient with renal carcinoma treated with temsirolimus. Nefrologia 2009;29(6):612
62. Gomez-Fernandez C, Garden BC, Wu S, et al. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Can 2012;48:340-6
63. Sibaud V, Dalenc F, Mourey L, Chevreau C. Paronychia and pyogenic granuloma induced by new anticancer mTOR inhibitors. Acta Derm Venereol 2009;91:584-5
64. Sarkaria JN, Galanis E, Wu W, et al. Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res 2010;16(22):5573-80
65. Teng CF, Wu HC, Tsai HW, et al. Novel feedback inhibition of surface antigen synthesis by mammalian target of rapamycin (mTOR) signal and its implication for hepatitis B virus tumorigenesis and therapy. Hepatology 2011;54:1199-207
66. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991;100:182-8
67. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307
68. Cordero E, Perez-Ordoñez A, Aydillo TA, et al. Therapy with m-TOR inhibitors decreases the response to the pandemic influenza A H1N1 vaccine in solid organ transplant recipients. Am J Transplant 2011;11(10):2205-13
69. Haidinger M, Poglitsch M, Geyeregger R, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010;185:3919-31
70. Araki K, Youngblood B, Ahmed R. The role of mTOR in memory CD8 T-cell differentiation. Immunol Rev 2010;235(1):234-43
71. Wang Y, Wang XY, Subjeck JR, et al. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines. Br J Can 2011;104:643-52
72. Wyeth Pharmaceuticals Letter, May 16, 2008
73. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008;300(19):2277-85
74. Zangari M, Fink LM, Elice F, et al. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27(29):4865-73
75. Fujisaka Y, Yamada Y, Yamamoto N, et al. A phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors. Jpn J Clin Oncol 2010;40(8):732-8
76. Punt CJA, Boni J, Bruntsch U, et al. Phase I and p cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003;14:931-7 (Pubitemid 36827210)
77. Blowers E, Hall K. Managing adverse events in the use of bevacizumab and chemotherapy. Br J Nurs 2009;18(6):351-6
78. Yang S, de Souza P, Alemao E, Purvis J. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-a. Br J Can 2010;102:1456-60
79. Zbrozek AS, Hudes G, Levy D, et al. Q-TWiST analysis of patients receiving temsirolimus or interferon alpha for treatment of advanced renal cell carcinoma. Pharmacoeconomics 2010;28(7):577-84
80. Spunt SL, Grupp SA, Vik TA, et al. Phase I study of temsirolimus in pediatric patients with recurrent/ refractory solid tumors. J Clin Oncol 2011;29:2933-40
81. Sun W, Modak S. Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. Oncol Targets Ther 2012;5:21-9
82. Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Can Res 2012;18:2625-31
83. Lunardi G, Armirotti A, Nicodemo M, et al. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series. Clin Ther 2009;31(8):1812-19
84. Pandya KJ, Dahlberg S, Hidalgo M, et al. A randomized, phase ii trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a Trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol 2007;2:1036-41 (Pubitemid 350059580)
85. Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma (RECORD 3). NCT00903175. ClinicalTrials.gov. Available from: http://clinicaltrial.gov/ct2/show/NCT00903175
86. Bhatt RS, Wang X, Zhang L, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010;9(10):2793-802
87. Gerullis H, Bergmann L, Maute L, et al. Feasibility of sequential use of sunitinib and temsirolimus in advanced renal cell carcinoma. Med Oncol 2010;27:373-8
88. Park K, Lee JL, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol 2012. [Epub ahead of print]
89. MacKenzie MJ, Rini BI, Elson P, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol 2011;22:145-8
90. Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76(2):430-4
91. Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib. NCT00474786. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00474786 [Last accessed 5 May 2012]
92. Pfizer Press Release, May 15, 2012: Pfizer provides topline results from phase 3 study of Torisel® as second-line treatment in advanced renal cell carcinoma (RCC). Available from: http://www.pfizer.com/news/press-release.jsp? guid=2012051500068 [Last accessed 7 November 12]
93. Phase II Study of Alternating Sunitinib and Temsirolimus. NCT01517243. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01517243 [Last accessed 5 May 2012]
94. Garcia VM, Basu B, Molife LR, et al. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Can Res 2012;18:3750-61
95. Merchan JR, Liu G, Fitch T, et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. Proc Am Soc Clin Oncol 2007;25:abstract 5034
96. Sunitinib Plus Temsirolimus in Patients With Renal Cell Carcinoma (RCC). NCT01122165. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/ show/NCT01122165 [Last accessed May 5 2012]
97. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009;7:24-7
98. Phase 1 Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors. NCT01548482. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/ show/NCT01548482 [Last accessed 5 May 2012]
99. Phase 1 Study of Axitinib and Temsirolimus in Solid Tumors. NCT01529138. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT01529138 [Last accessed 5 May 2012]
100. A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma. NCT00563147. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00563147 [Last accessed 5 May 2012]
101. Davies MA, Fox PS, Papadopoulos N, et al. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin Cancer Res 2012;18:1120-8
102. Négrier S, Gravis G, Pérol D, et al. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 2011;12:673-80
103. Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT). NCT00631371. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/ NCT00631371 [Last accessed 5 May 2012]
104. The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus, in Advanced Renal Cell Carcinoma [BeST]. NCT00378703. ClinTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT00378703 [Last accessed 5 May 2012]
105. Mills EJ, Rachlis B, O'Regan C. Thabane L, Perri D. Metastatic renal cell cancer treatments: an indirect comparison meta-analysis. BMC Cancer 2009;9:34-43
106. Coon IT, Hoyle M, Green C, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010;14(2):1-6